Publication:
Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis

dc.contributor.authorSasitorn Sirithoen_US
dc.contributor.authorTanawin Nopsoponen_US
dc.contributor.authorKrit Pongpirulen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherBumrungrad International Hospitalen_US
dc.contributor.otherJohns Hopkins Bloomberg School of Public Healthen_US
dc.date.accessioned2022-08-04T09:06:23Z
dc.date.available2022-08-04T09:06:23Z
dc.date.issued2021-12-01en_US
dc.description.abstractBackground: Therapeutic plasma exchanges (TPE) has been recommended for neuromyelitis optica spectrum disorders (NMOSD) as a rescue therapy after nonresponding from the high-dose steroid and as an early therapy in severe attacks. We performed a systematic review to evaluate whether therapeutic plasma exchange (TPE) is better than conventional intravenous methylprednisolone (IVMP) in neuromyelitis optica spectrum disorders (NMOSD) patients. Methods: Systematic search was conducted in five databases: PubMed, Embase, Scopus, Web of Science, and CENTRAL for randomized controlled trials and observational studies of TPE compared to intravenous steroid in NMOSD patients with neurological or visual outcomes in English without publication date restriction. Quality assessment was performed using ROB2 and ROBINS-I. The meta-analysis was done using a random-effects model. Pooled risk ratio (RR) or mean difference with a 95% CIs of efficacy outcomes included the Expanded Disability Status Scale (EDSS), visual acuity, and LogMAR were measured. Results: Of 3439 potential studies, seven were included in the systematic review (1211 attacks; 433 patients) and three studies were included in the meta-analysis. Compared to high dose steroid alone, the add-on TPE increases a chance for the returning of EDSS to baseline at discharge (RR 3.02, 95% CI 1.34–6.81) and last follow-up (RR 1.68, 95% CI 1.01–2.79) as well as improves visual acuity at last follow-up. Conclusion: TPE as an add-on therapy to high-dose steroid injection during an acute attack in NMOSD patients is associated with returning to baseline EDSS at discharge and last follow-up, and a trend to have a lower disability at 6–12 months.en_US
dc.identifier.citationJournal of Neurology. Vol.268, No.12 (2021), 4549-4562en_US
dc.identifier.doi10.1007/s00415-020-10257-zen_US
dc.identifier.issn14321459en_US
dc.identifier.issn03405354en_US
dc.identifier.other2-s2.0-85092287616en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/77655
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85092287616&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectNeuroscienceen_US
dc.titleTherapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysisen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85092287616&origin=inwarden_US

Files

Collections